Dr Reddy's expands its presence in UK
The expansion is expected to add value in the area of API manufacturing for the company.
Mumbai, October 8, 2012: The Indian pharma company, Dr Reddy’s Laboratories (DRL) has expanded its operations in the United Kingdom. The Custom Pharmaceutical Services (CPS) business has been expanded in the areas of development and manufacture of NCE (New Chemical Entities) APIs for use in pre-clinical through to commercial development at its facility in Mirfield, UK, the company said in a statement.
Equipped with state-of-the-art systems, the UK plant operates with a very high level of control and has been designed with the latest manufacturing compliance standards in mind.
"This expansion builds on our commitment to expand operations in UK and provide a superior network of manufacturing to support our global customer base,” said R Ananthanarayanan, President - Pharmaceutical Services and Active Ingredients business, Dr Reddy's.
The company has invested in multiple technology areas and the expansion can be expected to add significant value in the area of API manufacturing.
It is worth noting here that the Hyderabad-based drug company has eight API manufacturing facilities, all approved by health regulator FDA. Of these, six plants are in India and one each in Mexico and UK.